Results 41 to 50 of about 353,606 (241)

Expression and Clinical Significance of miR-26a and Pleomorphic Adenoma Gene 1 (PLAG1) in Invasive Pituitary Adenoma

Medical Science Monitor, 2016
Background Although pituitary adenoma is a malignant tumor, it can present as invasive growth in some cases. MicroRNA (miR)-26a has been found to be abnormally highly expressed in pituitary adenoma, indicating possible involvement in pathogenesis.
Chuan-ting Yu, Jixia Li, Fengnan Sun, Jinpeng Cui, Huali Fang, GuoLang Sui   +5 more
semanticscholar   +1 more source

Prenatal alcohol exposure increases the aggressiveness of estrogen‐induced pituitary tumors in male rats

Alcohol, Clinical and Experimental Research, EarlyView.
Prenatal alcohol exposure (PAE) enhances the development of aggressive pituitary tumors (PitNETs) in female rats. In this study, we found that PAE also promotes the development of PitNETs in male rats. Like in females, PAE treatment enhances the expression of stem cell and tumor aggressiveness genes and increases tumor cell proliferation rate ...
Shaista Chaudhary, Dipak K. Sarkar
wiley   +1 more source

Kisspeptin as a test of hypothalamic dysfunction in pubertal and reproductive disorders

Andrology, EarlyView.
Abstract The hypothalamic–pituitary–gonadal axis is regulated by the gonadotropin‐releasing hormone pulse generator in the hypothalamus. This is comprised of neurons that secrete kisspeptin in a pulsatile manner to stimulate the release of GnRH, and, in turn, downstream gonadotropins from the pituitary gland, and subsequently sex steroids and ...
Aureliane C. S. Pierret, Aaran H. Patel, Elisabeth Daniels, Alexander N. Comninos, Waljit S. Dhillo, Ali Abbara   +5 more
wiley   +1 more source

Cardiovascular safety of testosterone therapy—Insights from the TRAVERSE trial and beyond: A position statement of the European Expert Panel for Testosterone Research

Andrology, EarlyView.
Abstract Introduction Testosterone therapy has become a cornerstone treatment for men with hypogonadism, offering significant benefits such as improved sexual function, mood, muscle mass, and bone density. However, concerns about its cardiovascular safety have historically tempered its use.
Michael Zitzmann, Giulia Rastrelli, Robert D Murray, David Edwards, Yacov Reisman, Preethi Mohan Rao, Alexander Sahi, Thomas Hugh Jones, Alberto Ferlin, Eleni Armeni, Emiliano Corpas, Jann‐Frederik Cremers, Janine David, Stefan Arver, Leen Antonio, Giovanni Corona   +15 more
wiley   +1 more source

Histological criteria for atypical pituitary adenomas – data from the German pituitary adenoma registry suggests modifications

Acta Neuropathologica Communications, 2015
The term atypical pituitary adenoma (APA) was revised in the 2004 World Health Organization (WHO) classification of pituitary tumors. However, two of the four parameters required for the diagnosis of APAs were formulated rather vaguely (i.e., “extensive”
Christian P. Miermeister, S. Petersenn, M. Buchfelder, R. Fahlbusch, D. Lüdecke, A. Hölsken, M. Bergmann, Hans Ulrich Knappe, V. Hans, J. Flitsch, W. Saeger, R. Buslei   +11 more
semanticscholar   +1 more source

Pharmacokinetics and adverse effects of a long‐acting IM dopamine agonist: Cabergoline in healthy horses

Equine Veterinary Education, EarlyView.
Summary Background Pituitary pars intermedia dysfunction (PPID) is commonly treated with pergolide mesylate, a dopamine receptor agonist. Cabergoline is a dopamine receptor agonist that has shown activity on prolactin secretion in horses for up to 10 days.
H. Hess, A. Bracken, S. Rao, Y. Nout‐Lomas, D. Gustafson, L. Bass   +5 more
wiley   +1 more source

The Influence of Pituitary Adenoma Size on Vision and Visual Outcomes after Trans-Sphenoidal Adenectomy: A Report of 78 Cases

Journal of Korean Neurosurgical Society, 2015
Objective The aims of this study were to investigate the quantitative relationship between pituitary macroadenoma size and degree of visual impairment, and assess visual improvement after surgical resection of the tumor.
R. Ho, Hsiu-Mei Huang, J. Ho
semanticscholar   +1 more source

Dermatologic Features of Endocrine Tumor Syndromes—Systematic Review and Meta‐Analysis

International Journal of Dermatology, EarlyView.
ABSTRACT Endocrine tumor syndromes, including multiple endocrine neoplasia types 1, 2A, and 2B (MEN1, MEN2A, MEN2B), Carney complex (CNC), and PTEN hamartoma tumor syndrome (PHTS), are hereditary conditions characterized by multisystem tumor development.
Sára Pálla, Zseraldin Metyovinyi, Fanni Adél Meznerics, Arash Mirzahosseini, Judit Tőke, Miklós Tóth, Henriett Butz, Attila Patócs, Márta Medvecz   +8 more
wiley   +1 more source

Dopamine and prolactin in migraine: Mechanisms and potential therapeutic targets

Journal of Neuroendocrinology, EarlyView.
Prolactin and dopamine modulate migraine‐relevant trigeminal pathways. Hyperprolactinemia is associated with migraine‐like headache, and preclinical studies show that prolactin enhances trigeminal excitability, particularly in females. Dopamine inhibits prolactin release and may also directly suppress trigeminovascular activity via D2 receptors in the ...
Astrid Johannesson Hjelholt, Randi Maria Hanghøj Tei, Hans Christoph Diener, Jens Otto Lunde Jørgensen   +3 more
wiley   +1 more source

EGFL7 participates in regulating biological behavior of growth hormone–secreting pituitary adenomas via Notch2/DLL3 signaling pathway

Tumor Biology, 2017
Growth hormone–secreting pituitary adenoma accounts for about 20% of the third most common intracranial neoplasm—pituitary adenomas—which makes up 15% of all intracranial tumors.
Jianpeng Wang, Qian Liu, Hua Gao, Dehong Wan, Chuzhong Li, Zhaojian Li, Yazhuo Zhang   +6 more
doaj   +1 more source